NCT04209777

Brief Summary

It is a clinical trial conducted on smokers with chronic periodontitis in which the participants are divided into two groups and one group is provided with antibiotics while the other with probiotics as an adjunct to non-surgical therapy. The participants were assessed for change in probing pocket depths, attachment loss, bleeding on probing, plaque index and gingival index after 1-month and 3-month period.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
66

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Jul 2018

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 8, 2018

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 16, 2019

Completed
20 days until next milestone

Study Completion

Last participant's last visit for all outcomes

May 6, 2019

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

December 18, 2019

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 24, 2019

Completed
Last Updated

December 24, 2019

Status Verified

December 1, 2019

Enrollment Period

9 months

First QC Date

December 18, 2019

Last Update Submit

December 20, 2019

Conditions

Outcome Measures

Primary Outcomes (9)

  • Change in Probing pocket depth

    Probing pocket depth is recorded on six sites per tooth.

    At baseline.

  • Change in Probing pocket depth

    Probing pocket depth is recorded on six sites per tooth.

    After 1-month.

  • Change in Probing pocket depth

    Probing pocket depth is recorded on six sites per tooth.

    After 3-months.

  • Change in Clinical attachment level

    Clinical attachment level is recorded on six sites per tooth.

    At baseline.

  • Change in Clinical attachment level

    Clinical attachment level is recorded on six sites per tooth.

    After 1-month.

  • Change in Clinical attachment level

    Clinical attachment level is recorded on six sites per tooth.

    After 3-months.

  • Change in Bleeding on probing

    Bleeding on probing is recorded on six sites per tooth. Presence or absence of bleeding is checked.

    At baseline.

  • Change in Bleeding on probing

    Bleeding on probing is recorded on six sites per tooth. Presence or absence of bleeding is checked.

    After 1-month.

  • Change in Bleeding on probing

    Bleeding on probing is recorded on six sites per tooth. Presence or absence of bleeding is checked.

    After 3-months.

Secondary Outcomes (6)

  • Change in Plaque index

    At baseline.

  • Change in Plaque index

    After 1-month.

  • Change in Plaque index

    After 3-months.

  • Change in Gingival index

    At baseline.

  • Change in Gingival index

    After 1-month.

  • +1 more secondary outcomes

Study Arms (2)

Antibiotics

ACTIVE COMPARATOR

The antibiotic group is provided with amoxicillin capsules 500mg and metronidazole tablets 400mg three times a day for 7 days along with the placebo of probiotics twice daily for 30 days.

Drug: Antibiotics

Probiotics

EXPERIMENTAL

The probiotic group is provided with Lactobacillus-reuteri probiotics (2x10(8)CFU) twice daily after brushing for 30 days.

Drug: Probiotic Blend Chewable Tablet

Interventions

Lactobacillus-reuteri probiotics were used as an experimental drug.

Also known as: Scaling and root debridement.
Probiotics

Amoxicillin capsules 500mg and metronidazole tablets 400mg antibiotics were used as an active comparator.

Also known as: Scaling and root debridement.
Antibiotics

Eligibility Criteria

Age35 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • systemically healthy males or females.
  • at least 35 years of age with minimal 3 natural teeth in each quadrant excluding 3rd molar.
  • previously untreated moderate to severe generalized chronic periodontitis
  • were current smokers having ≥10 cigarettes /day.

You may not qualify if:

  • having periodontal therapy within the past 6 months.
  • have undergone antibiotics or long-term NSAIDS therapy within the past 6 months.
  • have an allergy to penicillin and metronidazole.
  • having either fixed or removable prosthesis.
  • pregnant or nursing females.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mehwish Ghazal

Karachi, Sindh, Pakistan

Location

Related Publications (9)

  • Ikram S, Hassan N, Baig S, Borges KJJ, Raffat MA, Akram Z. Effect of local probiotic (Lactobacillus reuteri) vs systemic antibiotic therapy as an adjunct to non-surgical periodontal treatment in chronic periodontitis. J Investig Clin Dent. 2019 May;10(2):e12393. doi: 10.1111/jicd.12393. Epub 2019 Jan 20.

  • Morales A, Carvajal P, Silva N, Hernandez M, Godoy C, Rodriguez G, Cabello R, Garcia-Sesnich J, Hoare A, Diaz PI, Gamonal J. Clinical Effects of Lactobacillus rhamnosus in Non-Surgical Treatment of Chronic Periodontitis: A Randomized Placebo-Controlled Trial With 1-Year Follow-Up. J Periodontol. 2016 Aug;87(8):944-52. doi: 10.1902/jop.2016.150665. Epub 2016 Mar 4.

  • Theodoro LH, Claudio MM, Nuernberg MAA, Miessi DMJ, Batista JA, Duque C, Garcia VG. Effects of Lactobacillus reuteri as an adjunct to the treatment of periodontitis in smokers: randomised clinical trial. Benef Microbes. 2019 Apr 19;10(4):375-384. doi: 10.3920/BM2018.0150. Epub 2019 Apr 1.

  • Vicario M, Santos A, Violant D, Nart J, Giner L. Clinical changes in periodontal subjects with the probiotic Lactobacillus reuteri Prodentis: a preliminary randomized clinical trial. Acta Odontol Scand. 2013 May-Jul;71(3-4):813-9. doi: 10.3109/00016357.2012.734404. Epub 2012 Nov 26.

  • Assem NZ, Alves MLF, Lopes AB, Gualberto EC Junior, Garcia VG, Theodoro LH. Antibiotic therapy as an adjunct to scaling and root planing in smokers: a systematic review and meta-analysis. Braz Oral Res. 2017 Jul 3;31:e67. doi: 10.1590/1807-3107BOR-2017.vol31.0067.

  • Grusovin MG, Bossini S, Calza S, Cappa V, Garzetti G, Scotti E, Gherlone EF, Mensi M. Clinical efficacy of Lactobacillus reuteri-containing lozenges in the supportive therapy of generalized periodontitis stage III and IV, grade C: 1-year results of a double-blind randomized placebo-controlled pilot study. Clin Oral Investig. 2020 Jun;24(6):2015-2024. doi: 10.1007/s00784-019-03065-x. Epub 2019 Oct 16.

  • Albandar JM. Adjunctive antibiotics with nonsurgical periodontal therapy improve the clinical outcome of chronic periodontitis in current smokers. J Evid Based Dent Pract. 2012 Sep;12(3 Suppl):63-6. doi: 10.1016/S1532-3382(12)70015-5.

  • Morales A, Gandolfo A, Bravo J, Carvajal P, Silva N, Godoy C, Garcia-Sesnich J, Hoare A, Diaz P, Gamonal J. Microbiological and clinical effects of probiotics and antibiotics on nonsurgical treatment of chronic periodontitis: a randomized placebo- controlled trial with 9-month follow-up. J Appl Oral Sci. 2018 Jan 18;26:e20170075. doi: 10.1590/1678-7757-2017-0075.

  • Ikram S, Hassan N, Raffat MA, Mirza S, Akram Z. Systematic review and meta-analysis of double-blind, placebo-controlled, randomized clinical trials using probiotics in chronic periodontitis. J Investig Clin Dent. 2018 Aug;9(3):e12338. doi: 10.1111/jicd.12338. Epub 2018 Mar 31.

MeSH Terms

Conditions

Periodontal DiseasesSmoking

Interventions

Tooth ExfoliationAnti-Bacterial Agents

Condition Hierarchy (Ancestors)

Mouth DiseasesStomatognathic DiseasesBehavior

Intervention Hierarchy (Ancestors)

Dental Physiological PhenomenaDigestive System and Oral Physiological PhenomenaAnti-Infective AgentsTherapeutic UsesPharmacologic ActionsChemical Actions and Uses

Study Officials

  • Shahbaz Ahmed, BDS/FCPS

    Dow University of Health Sciences

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

December 18, 2019

First Posted

December 24, 2019

Study Start

July 8, 2018

Primary Completion

April 16, 2019

Study Completion

May 6, 2019

Last Updated

December 24, 2019

Record last verified: 2019-12

Data Sharing

IPD Sharing
Will share

The data will be available for sharing after 6-months of publication.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
The data will be available after the publication of the study for 1 year.
Access Criteria
Contact the principal investigator through email.

Locations